Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
UK is a gateway Country they say.
If a fund had a lopsided Long-Short position, this would be the repeated statements.
Most companies don't comment on pending applications, nor pending litigation.
The news jdheart referenced appears to be the SA article, which is a Nothingburger article again.
Any WHO INN action from the 75th Consultation on International Nonproprietary Names re: Canpuldencel-T over the next few days?
Truth hurts...lol lol
Guidelines are nonbinding, usually.
HL, you have reminded me of what is probably going on! This makes me feel so much more pro-management !! These two acquisition signs, company silence and anti-CEO Board comments, are so often discussed here. Very enlightening.
Do you actually think Management cares about the stock price?
I am kept up at night by NWBO.... how can I get more shares !! I only make so much on my paycheck.... my worldly possessions already sold for shares... just got $350 from Gov. Newsom, that was 500 more shares... could I really sell my grandmothers wedding ring??? nahhh..
US is dominant market because of very high prices, so, the numbers are skewed a bit. Your a numbers guy, you know that.
Nonocure does have 'device' approved. Revenue, yes. Hence, able to fund more trials. NWBO will take the same route when they have the impending approval and revenue generation over the coming years.
The TTF trials will be interesting to see if they hurt healthy cells division.
What is Nonocure doing with the money? Wasting it as sponsorship and ad space.
Did UK regulators approve it?? Clearly, NWBO is UK centric right now... any narrative to make is about the FDA is a poor talking point.
Stock price means nothing when someone is kicking your grandmother in the shins.
lol . sure/sure why not/not... LOL
YTD, we are TWICE as good as S&P500.
S&P 500 -25.10%
NWBO - 12.47%
That is GREAT management. Outperforming the market !!
5 Year, we are up 295%... heck ya !!
I agree with Midwest Hedgie on this one.
Landmark OS on hard to treat GBM is very well received by shareholders. It's non-shareholders that are upset.
Orange orange orange
When this all comes together, I will have zero vanity nor care for my manboobs to be removed. I will continue to go sockless in leather shoes on a hot day.
And Yikes.."The inner or second of the three toes is fitted with a long, straight, murderous nail which can sever an arm or eviscerate an abdomen with ease"
This might be about to happen, three toes crossed for luck...
Cassowary, a living dinosaur. Often called "the world's most dangerous bird"
They still roam the Earth. NWBio is similar... often dismissed as extinct, but after honing survival skills developed after the approach and attack of enemies, they are still here. It demands such a skillset to be so rare, only the smartest survive, others do and will perish. 1/866.
I feel that Dr. Murthy knew this was an exceptional match for NWbio's needs. I believe he knows this will increase the stock price, hence, he got lucky find at a garage sale. Worth much more than he was paid.
the yare dumb. had a chance to take another path, missed it.
Are you thinking they will use "C" shares as payment?? LOL.
hey, maybe Linda's 'healthbank' is back in business. LOL.
But seriously, Advent has some Serious Cryostorage Capacity... they are not messing around.
Do you have proof of no agreement? no proof of, is not proof of not.
Where is the rule to be compliant with guidance... as it is just that, guidance, and not a rule.
I agree the trial adapted from the original protocol to the EU version which is now OS in the USA.
I think Judge Judy would rip him apart...lol.
For me, it's always the broad strokes of things...
Q to Judy: does a trial failure depress the stock price?
Q to Judy: did trial get reported as failed by major biotech writer?
Q to Judy: did trial actually fail OS?
A: yes.
A: yes.
A: no.
Plaintiff wins and gets his dog too.
"Contains Nonbinding Recommendations" Thanks.
It feels the "us versus them" narrative is being Frothed up like a Latte.. any ideas why ??
Lol. Who says that? Lol
I meant proactiveinvestors com
LOL. Like Proactive? LOL.
Why PR a scientific event? Not usually done. The PR did sound forced a little, like they didn't want to have one out there. IMO.
My understanding was they tried to halt, by OTC would not. Guess we know why now. Plus, a scientific presentation, covering only basic survival data, I get the 'no to halt.'
If the approval process is moving forward, a JA is really not that important anymore in some ways. Things may be always changing as we are in silent fluidity. (hence, not many statements that people will hold in SEC filings, with threat of perjury. lol) IMHO.
My biggest issue with the attack was that darn intra-day low... $0.38-ish... how long was someone calling that out?? Who has access to brokerage account stop-loss orders ??? Who could have possibly known? The collusion implications are worthy of an investigation and victims to be pissed off.
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company’s lead product, DCVax-L, is currently in a 348-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. The Company’s second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers. The Company has also conducted a Phase I/II trial with DCVax for late stage ovarian cancer together with the University of Pennsylvania. The Company previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
The companies true focus DCVAX, DCVAX, DCVAX.